Advertisement

Prevention of Mother to Child Transmission of HIV

  • Kimesh L. NaidooEmail author
Chapter
  • 22 Downloads

Abstract

Prevention of HIV transmission from mother to child (PMTCT) has transformed the paediatric HIV epidemic. Understanding the complex transmission of HIV in-utero, intra-partum and post-partum remains a challenge but this holds the possibility of further innovative advances in PMTCT strategies. Universal HIV testing, and the careful usage and choice of antiretroviral drugs and infant nutritional practices forms the core of PMTCT strategies to ensure a healthy mother and a HIV uninfected child Pre-conceptual, antepartum and postpartum care of HIV infected women needs to encompass evidence based PMTCT strategies into accessible, comprehensive programmes and this holds the potential for the elimination of mother to child transmission in all contexts.

Keywords

Pregnant Women PMTCT Vertical transmission In-utero Intra-partum Antiretroviral Ante-partum Teratogenic 

References

  1. 1.
    World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Geneva: World Health Organization; 2010.Google Scholar
  2. 2.
    World Health Organization. PMTCT strategic vision 2010–2015: preventing mother-to-child transmission of HIV to reach the UNGASS and millennium development goals. Geneva: World Health Organization; 2010.Google Scholar
  3. 3.
    Kourtis AP, Bulterys M, Nesheim R, Lee FK. Understanding the timing of HIV transmission from mother to infant. JAMA. 2001;285:709–12.CrossRefGoogle Scholar
  4. 4.
    Zack JA, Haislip AM, Krogstad P, et al. Incompletely reverse-transcribed HIV-1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol. 1992;66:1717–25.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Lee FK, Scinicariello F, Ou CY, et al. Partially reverse transcribed HIV genome in uninfected HIV-exposed infants. In: Presented at the 11th conference on retroviruses and opportunistic infections. San Francisco (CA), February 8–12, 2004.Google Scholar
  6. 6.
    Kourtis AP, Lee FK, Abrams EJ, Jamieson DJ, Bulterys M. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect Dis. 2006;6(11):726–7.CrossRefGoogle Scholar
  7. 7.
    Fawzi W, Msamanga G, Spiegelman D, et al. Transmission of HIV-1 through breastfeeding among women in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr. 2002;31:331–8.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Miotti PG, Taha TE, Kumwenda N, et al. HIV transmission during breastfeeding: a study in Malawi. JAMA. 1999;282:744–9.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Kourtis AP, Butera ST, Ibegbu C, et al. Breast milk and HIV-1: vector of transmission or vehicle of protection? Lancet Infect Dis. 2003;3:786–93.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Luzuriaga K, Mofenson LM. Challenges in the elimination of pediatric HIV-1 infection. N Engl J Med. 2016;374(8):761–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: pathogenesis, mechanisms and pathways. Clin Perinatol. 2010;37(4):721–37.PubMedCrossRefGoogle Scholar
  12. 12.
    Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and the mother to child transmission of HIV-1: the French Perinatal Cohort Studies. J Infect Dis. 1997;175:172–5.PubMedCrossRefGoogle Scholar
  13. 13.
    The European Collaborative Study. Maternal viral load and vertical transmission of HIV: an important factor but not the only one. AIDS. 1999;13:1377–85.CrossRefGoogle Scholar
  14. 14.
    Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal HIV transmission. N Engl J Med. 1999;341:394–402.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341(6):385–93.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Read JS. Prevention of mother-to-child transmission of HIV. In: Zeichner S, Read J, editors. Textbook of pediatric HIV care. Cambridge: Cambridge University Press; 2005. p. 111–33.CrossRefGoogle Scholar
  17. 17.
    Lehman DA, Farquhar C. Biological mechanisms of vertical HIV-1 transmission. Rev Med Virol. 2007;17:381–403.CrossRefGoogle Scholar
  18. 18.
    Dunn D, Newell ML. Vertical transmission of HIV. Lancet. 1992;339:364–5.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Renjifo B, Chung M, Gilbert P, et al. In utero transmission of quasispecies among HIV type 1 genotypes. Virology. 2003;307:278–82.PubMedCrossRefGoogle Scholar
  20. 20.
    Dickover RE, Garratty EM, Plaeger S, et al. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol. 2001;75:2194–203.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Kwiek JJ, Russell ES, Dang KK, et al. The molecular epidemiology of HIV-1 envelope diversity during HIV-1 subtype C vertical transmission in Malawian mother–infant pairs. AIDS. 2008;22:863–71.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Wolinsky SM, Wike CM, Korber BT, et al. Selective transmission of HIV-1 variants from mothers to infants. Science. 1992;255:1134–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Ahmad N, Baroudy BM, Baker RC, et al. Genetic analysis of HIV-1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol. 1995;69:1001–12.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Derdeyn CA, Hunter E. Viral characteristics of transmitted HIV. Curr Opin HIV AIDS. 2008;3:16–21.PubMedCrossRefGoogle Scholar
  25. 25.
    DeRossi A. Virus–host interactions in paediatric HIV infection. Curr Opin HIV AIDS. 2007;2:399–404.CrossRefGoogle Scholar
  26. 26.
    Braida L, Boniotto M, Pontillo A, et al. A single nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children. AIDS. 2004;18:1598–600.PubMedCrossRefGoogle Scholar
  27. 27.
    Milanese M, Segat L, Pontillo A, et al. DEFB1 gene polymorphisms and increased risk of HIV-1 infection in Brazilian children. AIDS. 2006;20:1673–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Kliks SC, Wara DW, Landers DV, et al. Features of HIV-1 that could influence maternal–child transmission. JAMA. 1994;272:467–74.PubMedCrossRefGoogle Scholar
  29. 29.
    Scarlatti G, Albert J, Rossi V, et al. Mother to child transmission of HIV-1: correlation with neutralizing antibodies against primary isolates. J Infect Dis. 1993;168:207–10.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Tranchat C, Van de Perre P, Simonon-Sorel A, et al. Maternal humoral factors associated with perinatal HIV-1 transmission in a cohort from Kigali, Rwanda, 1988–94. J Infect. 1999;39:213–20.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    DeMaria A, Cirrilo C, Moretta L. Occurrence of HIV-1 specific cytolytic T cell activity in apparently uninfected children born to HIV-1 infected mothers. J Infect Dis. 1994;170:1296–9.CrossRefGoogle Scholar
  32. 32.
    Rowland-Jones S, Nixon DR, Aldhous MC, et al. HIV-1 specific cytotoxic T cell activity in an HIV-exposed but uninfected infant. Lancet. 1993;341:860–1.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Kuhn L. Milk mysteries: why are women who exclusively breastfeed less likely to transmit HIV during breastfeeding? Clin Infect Dis. 2010;50:770–2.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    MacDonald KS, Embree J, Nagelkerke NJ, et al. The HLA A2/6802 super type is associated with reduced risk of perinatal HIV-1 transmission. J Infect Dis. 2001;183:503–6.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Winchester R, Chen Y, Rose S, et al. Transmission of HIV-1 from an infected woman to her offspring during gestation and delivery was found to be influenced by the infant’s major histocompatibility complex class II DRB1 alleles. Proc Natl Acad Sci U S A. 1995;92:12371–8.CrossRefGoogle Scholar
  36. 36.
    Winchester R, Pitt J, Charurat M, et al. Mother to child transmission of HIV-1: strong association with certain maternal HLA-B alleles independent of viral load implicates innate immune mechanisms. J Acquir Immune Defic Syndr. 2004;36:659–70.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Aikhionbare FO, Hodge T, Kuhn L, et al. Mother-to-child discordance in HLA-G exon 2 is associated with a reduced risk of perinatal HIV-1 transmission. AIDS. 2001;15:2196–8.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Farquhar C, Rowland-Jones S, Mbori-Ngacha D, et al. Human leukocyte antigen (HLA) B∗18 and protection against mother-to-child HIV type 1 transmission. AIDS Res Hum Retrovir. 2004;20:692–7.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    St Louis M, Kamenga M, Brown C, et al. Risk of perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. J Am Med Assoc. 1993;269:2853–9.CrossRefGoogle Scholar
  40. 40.
    Wabwire-Mangen F, Gray R, Mmiro F, et al. Placental membrane inflammation and risks of maternal to child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr. 1992;22:379–85.CrossRefGoogle Scholar
  41. 41.
    Taha TE, Gray RH. Genital tract infections and perinatal transmission of HIV. Ann N Y Acad Sci. 2000;918:84–98.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Chen KT, Segu M, Lumey LH, et al. Genital herpes simplex virus infection and perinatal transmission of HIV. Obstet Gynecol. 2005;106:1341–8.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Drake AL, John-Stewart GC, Wald A, et al. Herpes simplex virus type 2 and risk of intrapartum HIV transmission. Obstet Gynecol. 2007;109:403–9.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Kumwenda N, Miotti P, Taha T, et al. Antenatal vitamin A supplementation increases birthweight and decreases anemia, but does not prevent HIV transmission or decrease mortality in infants born to HIV-infected women in Malawi. Clin Infect Dis. 2002;35:618–24.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Coutsoudis A, Pillay K, Spooner E, et al. Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child transmission in Durban, South Africa. AIDS. 1999;13:1517–24.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Fawzi W, Msamanga G, Hunter D, et al. Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS. 2002;16:1935–44.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Humphrey JH, Iliff PJ, Marinda ET, et al. Effects of a single large dose of vitamin A, given during the postpartum period to HIV-positive women and their infants, on child HIV infection, HIV-free survival, and mortality. J Infect Dis. 2006;193:860–71.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Baeten J, Mostad S, Hughes M, et al. Selenium deficiency is associated with shedding of HIV-1 infected cells in the female genital tract. J Acquir Immune Defic Syndr. 2001;26:360–4.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Kupka R, Garland M, Msamanga G, et al. Selenium status, pregnancy outcomes, and mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;29:201–10.Google Scholar
  50. 50.
    Embree JE, Njenga D, Data P, et al. Risk factors for postnatal mother–child transmission of HIV-1. AIDS. 2000;14:2535–41.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Lunney KM, Iliff P, Mutasa K, et al. Associations between breast milk viral load, mastitis, exclusive breast-feeding, and postnatal transmission of HIV. Clin Infect Dis. 2010;50:762–9.PubMedGoogle Scholar
  52. 52.
    International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies. AIDS. 2001;15:357–68.CrossRefGoogle Scholar
  53. 53.
    Mandelbrot L, Mayaux M, Bongain A, et al. Obstetric factors and mother-to-child transmission of HIV-1: the French perinatal cohorts. Am J Obstet Gynecol. 1996;175:661–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Kuhn L, Abrams E, Matheson P, et al. Timing of maternal–infant HIV transmission: association between intrapartum factors and early polymerase chain reaction results. AIDS. 1997;11:429–35.PubMedCrossRefGoogle Scholar
  55. 55.
    The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of HIV-1. N Engl J Med. 1999;340:977–87.CrossRefGoogle Scholar
  56. 56.
    European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet. 1992;339:1007–12.CrossRefGoogle Scholar
  57. 57.
    Van Dyke RB, Korber BT, Popek E, et al. The Ariel project. A prospective cohort study of maternal–child transmission of HIV-1 in the era of maternal antiretroviral therapy. J Infect Dis. 1999;179:319–28.PubMedCrossRefGoogle Scholar
  58. 58.
    Pillay T, Adhikari M, Coovadia HM, Moodley J, Khan M, Sullivan JL. In utero HIV infection in pregnancies complicated by tuberculosis in Durban, South Africa. Arch Dis Child Fetal Neonatal Ed. 2004;89:F468–9.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175–82.PubMedCrossRefGoogle Scholar
  60. 60.
    WHO. Global AIDS update. Ending AIDS towards the 90–90-90 targets. UNAIDS: Geneva; 2017.Google Scholar
  61. 61.
    World Health Organization. WHO validates elimination of mother to- child transmission of HIV and syphilis in Cuba? Geneva: World Health Organization; 2015.Google Scholar
  62. 62.
    Burton R, Giddy J, Stinson K. Prevention of mother-to-child transmission in South Africa: an ever-changing landscape. Obstet Med. 2015;8(1):5–12.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Mayosi BM, Lawn JE, van Niekerk A, et al. Health in South Africa: changes and challenges since 2009. Lancet. 2012;380:2029–43.PubMedCrossRefGoogle Scholar
  64. 64.
    National Department of Health. National HIV and Syphilis antenatal sero-prevalence survey in South Africa 1998. Report. Pretoria, 1999.Google Scholar
  65. 65.
    National Department of Health. National HIV and syphilis seroprevalence survey in South Africa, 2000. Report. Pretoria, 2001.Google Scholar
  66. 66.
    Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–80.PubMedCrossRefGoogle Scholar
  67. 67.
    Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET012 randomised trial. Lancet. 1999;354:795–802.PubMedCrossRefGoogle Scholar
  68. 68.
    Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34(Suppl 1):S21–33.PubMedCrossRefGoogle Scholar
  69. 69.
    Hitti J, Frenkel LM, Stek AM, PACTG 1022 Study Team, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772–6.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24:1461–70.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    National Department of Health. Antiretroviral Treatment (ART) in adults. Pretoria, 2004.Google Scholar
  72. 72.
    Coutsoudis A, Pillay K, Kuhn L, South African Vitamin A Study Group, et al. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban. AIDS. 2001;15:379–87.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Kuhn L, Aldrovandi G. Survival and health benefits of breastfeeding versus artificial feeding in infants of HIV-infected women: developing versus developed world. Clin Perinat. 2010;37:843–62.CrossRefGoogle Scholar
  74. 74.
    World Health Organisation. Guidelines on HIV and infant feeding. Geneva: WHO; 2010.Google Scholar
  75. 75.
    National Department of Health. The Tshwane declaration of support for breastfeeding in South Africa. S Afr J Clin Nutr. 2011;24:214.Google Scholar
  76. 76.
    White AB, Mirjahangir JF, Horvath H, Anglemyer A, Read JS. Antiretroviral interventions for preventing breast milk transmission of HIV. Cochrane Database Syst Rev. 2014;10:CD011323.Google Scholar
  77. 77.
    Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed 3 Jan 2019.
  78. 78.
    World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018.Google Scholar
  79. 79.
    National Consolidated Guidelines. For the prevention of Mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. National Department of Health. South Africa, April 2015.Google Scholar
  80. 80.
    Mirochnick M, Capparelli E. Pharmacokinetics of antiretroviral in pregnant women. Clin Pharmacokinet. 2004;43(15):1071–87.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol. 2008;66(2):179–95.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Bollen P, Colbers A, Schalkwijk S, et al. A comparison of the pharmacokinetics of dolutegravir during pregnancy and postpartum. In: Presented at 18th international workshop on clinical pharmacology of antiviral therapy, Chicago, IL; 2017.Google Scholar
  83. 83.
    Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12(14):1735–44.CrossRefPubMedGoogle Scholar
  84. 84.
    Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46(3):716–23.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA. Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. Antimicrob Agents Chemother. 2008;52(8):2825–30.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Joint United Nations Programme on HIV/AIDS. Progress report on the global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Paediatrics and Child HealthNelson R Mandela School of Medicine, University of Kwa-Zulu Natal (UKZN)DurbanSouth Africa

Personalised recommendations